<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04296266</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-32994</org_study_id>
    <nct_id>NCT04296266</nct_id>
  </id_info>
  <brief_title>Human Salivary Gland Disposition of Alda-341 in Patients Undergoing Salivary Gland Surgery</brief_title>
  <official_title>Human Salivary Gland Disposition of Alda-341 in Patients Undergoing Salivary Gland Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is determine salivary gland disposition of d-limonene, the primary
      component in citrus peel and a common dietary supplement.

      Salivary gland tissue and saliva will be collected to determine concentration of d-limonene
      and its metabolites in these tissues.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To determine the bioavailability of Alda-341 in salivary gland tissue.

      Secondary Objective: To determine the bioavailability of Alda-341 in saliva and blood
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">December 21, 2017</completion_date>
  <primary_completion_date type="Actual">December 18, 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability of Alda-341 in salivary gland tissue using GCMS</measure>
    <time_frame>2 week</time_frame>
    <description>Bio availability of Alda-341 in salivary gland tissue will be measured using gas chromatography mass spectrometry (GCMS). The scale is is 4ng/mL - 8000ng/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bioavailability of Alda-341 in saliva and blood</measure>
    <time_frame>2 week</time_frame>
    <description>Bio availability of Alda-341 in saliva and blood will be measured using gas chromatography mass spectrometry (GCMS). The scale is is 4ng/mL - 8000ng/mL.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Submandibular Gland Tumor</condition>
  <condition>Parotid Gland Tumor</condition>
  <arm_group>
    <arm_group_label>Alda-341 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alda-341 treatment at 2 g/day for 14 days up until the day before regular medical care surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alda-341</intervention_name>
    <description>Dietary supplement d-limonene orally administered as a drug.</description>
    <arm_group_label>Alda-341 treatment</arm_group_label>
    <other_name>d-limonene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elected to undergo surgery for recent diagnosis of parotid or submandibular gland
             tumor

          -  Ability to adhere to study visit schedule and other protocol requirements

          -  Operable candidate base on the surgeon's note

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Nursing or pregnant

          -  Diagnosis of kidney disease, history of renal disease with creatinine &gt; 1.5 mg/dL, or
             currently on dialysis

          -  Diagnosis of end stage liver disease

          -  Any unstable medical condition

          -  Use of chemotherapy or radiotherapy within 4 weeks before first dose of study dietary
             supplement

          -  Unwilling to stop dietary supplements 3 weeks before first dose of study dietary
             supplement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quynh-Thu Le, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parotid Neoplasms</mesh_term>
    <mesh_term>Submandibular Gland Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

